Acceleron Pharma Inc., of Cambridge, Mass., reported preliminary results from an ongoing phase II trial testing luspatercept in 106 patients with lower-risk myelodysplastic syndromes. Luspatercept is a modified activin receptor type IIB fusion protein being developed with Summit, N.J.-based Celgene Corp.